Market Overview

UPDATE: Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels


Perrigo Company (Nasdaq: PRGO) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough's Claritin-D® 12 hour extended release tablets.

Claritin-D® 12 is indicated for the treatment of nasal allergy symptoms. Its estimated annual sales are approximately $111 million, according to data provided by Wolters, Kluwer.

Posted-In: News FDA


Related Articles (PRGO)

View Comments and Join the Discussion!